Black Hawk Acquisition Corporation BKHA

No annual revenue total was found in Black Hawk Acquisition Corporation's SEC filings.

Black Hawk Acquisition Corporation (BKHA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).

Revenue
—
Net income (TTM)
$1.30M
-37.7% vs year-ago TTM
Operating cash flow (TTM)
$-560,069
+8.0% vs year-ago TTM
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
4.15M
-53.5% vs prior year
Net cash
—
Operating margin
—

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BKHA (Nasdaq), BKHAR (Nasdaq), BKHAU (Nasdaq)
Fiscal year ends
November 30
Headquarters
Danville, CA
SEC filer status
, Emerging growth company
SEC CIK
2000775

Other Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Nov 30, 2025
FY 2024
Nov 30, 2024
Operating income
-$915,510
-$576,076
Net income
$1.3M
$1.9M
Operating cash flow
-$650,321
-$553,665
Total assets
$23.9M
$72.1M
Total liabilities
$3.9M
$2.5M
Stockholders' equity
-$3.8M
-$2.2M
Cash and investments
$0
$0

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Other events
Oct 23, 2026 Oct 22, 2026
8-K Current report
Shareholder vote results
Oct 13, 2026 Oct 13, 2026
10-Q Quarterly report Oct 6, 2026 Aug 31, 2026
8-K Current report
Material agreement, Unregistered share sale
Sep 24, 2026 Sep 22, 2026
8-K Current report
Other events
Sep 22, 2026 Sep 22, 2026
8-K Current report
Material agreement, New debt, Unregistered share sale
Aug 26, 2026 Aug 21, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.